Innate Pharma receives $5M from its Monster-deal with BMS

This milestone payment from Bristol-Myers Squibb is part of the lirilumab licensing agreement, the monster immuno-oncology deal of €408M ($465M) signed in July 2011.

This payment was triggered by the dosing of the first patient in a phase II trial of the monoclonal antibody drug lirilumab, in combination with rituximab in patients with relapsed/refractory or high-risk untreated Chronic Lymphocytic Leukemia (CLL).

herve_brailly_innate_pharma

Hervé Brailly, Founder & CEO of Innate Pharma

This milestone marks the start of a new Phase II trial of lirilumab in hemato-oncology outside of Acute Myeloid Leukemia. We are pleased with the broad clinical program for lirilumab, and expect that results will begin to be delivered in 2016” – Hervé Brailly, CEO and co-founder of Innate Pharma.

In total, 6 trials are currently being performed with lirilumab, testing a range of solid and hematological cancer indications, multiple rationales and combinations with cytotoxic antibodies, and checkpoint inhibitors in chemotherapy.

Even if it is a small payment (form the biotech industry’s perspective, at least), it primarily shows Innate-Pharma is moving forward in the collaboration and delivers good results.

I visited Innate Pharma back in the summer 2012 and I was pretty impressed by its office located in the middle of Marseille’s “Calanques” – absolutely beautiful! This Biotech is now one of Europe’s most advanced in Immuno-oncology and has a market cap of €680M.

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.